1 Kwong, G. A. et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol 31, 63-70, doi:10.1038/nbt.2464 (2013).
2 Ronald, J. A., Chuang, H. Y., Dragulescu-Andrasi, A., Hori, S. S. & Gambhir, S. S. Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker. Proc Natl Acad Sci U S A 112, 3068-3073, doi:10.1073/pnas.1414156112 (2015).
3 Hori, S. S. & Gambhir, S. S. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci Transl Med 3, 109ra116, doi:10.1126/scitranslmed.3003110 (2011).
4 Badeau, B. A., Comerford, M. P., Arakawa, C. K., Shadish, J. A. & DeForest, C. A. Engineered modular biomaterial logic gates for environmentally triggered therapeutic delivery. Nat Chem 10, 251-258, doi:10.1038/nchem.2917 (2018).
5 Koo, K. M., Mainwaring, P. N., Tomlins, S. A. & Trau, M. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nat Rev Urol 16, 302-317, doi:10.1038/s41585-019-0178-2 (2019).
6 Aalipour, A. et al. Engineered immune cells as highly sensitive cancer diagnostics. Nat Biotechnol 37, 531-539, doi:10.1038/s41587-019-0064-8 (2019).
7 Mannocci, L. Z., Y.; Scheuermann, J.; Leimbacher, M., Bellis, G.D.; Rizzi, E.; Dumelin, C.; Melkko, S.; Neri, D. High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries. Proc Natl Acad Sci U S A 105, 17670-17675, doi:https://doi.org/10.1073/pnas.0805130105 (2008).
8 Burgess, D. J. Spatial transcriptomics coming of age. Nat Rev Genet 20, 317, doi:10.1038/s41576-019-0129-z (2019).
9 Ullal, A. V. et al. Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6, 219ra219, doi:10.1126/scitranslmed.3007361 (2014).
10 Dahlman, J. E. et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc Natl Acad Sci U S A 114, 2060-2065, doi:10.1073/pnas.1620874114 (2017).
11 Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385-389, doi:10.1038/s41586-019-1272-6 (2019).
12 Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell 164, 57-68, doi:10.1016/j.cell.2015.11.050 (2016).
13 Chabon, J. J. et al. Integrating genomic features for non-invasive early lung cancer detection. Nature 580, 245-251, doi:10.1038/s41586-020-2140-0 (2020).
14 Sun, K. et al. Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Res 29, 418-427, doi:10.1101/gr.242719.118 (2019).
15 Larson, M. H., Pan, W., Kim, H.J. et al. . A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection. Nat Commun 12, 2357, doi:https://doi.org/10.1038/s41467-021-22444-1 (2021).
16 Smith, C. I. E. & Zain, R. Therapeutic Oligonucleotides: State of the Art. Annu Rev Pharmacol Toxicol 59, 605-630, doi:10.1146/annurev-pharmtox-010818-021050 (2019).
17 Tabrizi, S. J. et al. Targeting Huntingtin Expression in Patients with Huntington's Disease. N Engl J Med 380, 2307-2316, doi:10.1056/NEJMoa1900907 (2019).
18 Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35, 238-248, doi:10.1038/nbt.3765 (2017).
19 Chen, J. S. et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science 360, 436-439, doi:10.1126/science.aar6245 (2018).
20 Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat Med 19, 1423-1437, doi:10.1038/nm.3394 (2013).
21 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674, doi:10.1016/j.cell.2011.02.013 (2011).
22 Gootenberg, J. S. et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 360, 439-444, doi:10.1126/science.aaq0179 (2018).
23 Liu, J. J. et al. CasX enzymes comprise a distinct family of RNA-guided genome editors. Nature 566, 218-223, doi:10.1038/s41586-019-0908-x (2019).
24 English, M. A. et al. Programmable CRISPR-responsive smart materials. Science 365, 780-785, doi:10.1126/science.aaw5122 (2019).
25 Gootenberg, J. S. et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 356, 438-442, doi:10.1126/science.aam9321 (2017).
26 Myhrvold, C. et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science 360, 444-448, doi:10.1126/science.aas8836 (2018).
27 Harrington, L. B. et al. Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science 362, 839-842, doi:10.1126/science.aav4294 (2018).
28 Stein, C. A. & Castanotto, D. FDA-Approved Oligonucleotide Therapies in 2017. Mol Ther 25, 1069-1075, doi:10.1016/j.ymthe.2017.03.023 (2017).
29 Shen, W. et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol 37, 640-650, doi:10.1038/s41587-019-0106-2 (2019).
30 Kim, J. et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N Engl J Med 381, 1644-1652, doi:10.1056/NEJMoa1813279 (2019).
31 Dudani, J. S., Ibrahim, M., Kirkpatrick, J., Warren, A. D. & Bhatia, S. N. Classification of prostate cancer using a protease activity nanosensor library. Proc Natl Acad Sci U S A 115, 8954-8959, doi:10.1073/pnas.1805337115 (2018).
32 Morrison, C. Nanobody approval gives domain antibodies a boost. Nat Rev Drug Discov 18, 485-487, doi:10.1038/d41573-019-00104-w (2019).
33 Massa, S. et al. Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging. Bioconjug Chem 25, 979-988, doi:10.1021/bc500111t (2014).
34 Kirley, T. L., Greis, K. D. & Norman, A. B. Selective disulfide reduction for labeling and enhancement of Fab antibody fragments. Biochem Biophys Res Commun 480, 752-757, doi:10.1016/j.bbrc.2016.10.128 (2016).
35 Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82, 775-797, doi:10.1146/annurev-biochem-063011-092449 (2013).
36 Fridy, P. C. et al. A robust pipeline for rapid production of versatile nanobody repertoires. Nat Methods 11, 1253-1260, doi:10.1038/nmeth.3170 (2014).
37 Danino, T. et al. Programmable probiotics for detection of cancer in urine. Sci Transl Med 7, 289ra284, doi:10.1126/scitranslmed.aaa3519 (2015).
38 Hynes, R. O. & Naba, A. Overview of the matrisome--an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 4, a004903, doi:10.1101/cshperspect.a004903 (2012).
39 Naba, A. et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 11, M111 014647, doi:10.1074/mcp.M111.014647 (2012).
40 Kirkpatrick, J. D. et al. Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Sci Transl Med 12, doi:10.1126/scitranslmed.aaw0262 (2020).
41 Devoogdt, N. et al. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A 100, 5778-5782, doi:10.1073/pnas.1037154100 (2003).
42 Pawar, N. R., Buzza, M. S. & Antalis, T. M. Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2-Mediated Signaling: Co-Conspirators in Cancer Progression. Cancer Res 79, 301-310, doi:10.1158/0008-5472.CAN-18-1745 (2019).
43 Fayard, B. et al. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Res 69, 5690-5698, doi:10.1158/0008-5472.CAN-08-4573 (2009).
44 Kwong, G. A. et al. Mathematical framework for activity-based cancer biomarkers. Proc Natl Acad Sci U S A 112, 12627-12632, doi:10.1073/pnas.1506925112 (2015).
45 Kaminski, M. M. et al. A CRISPR-based assay for the detection of opportunistic infections post-transplantation and for the monitoring of transplant rejection. Nat Biomed Eng, doi:10.1038/s41551-020-0546-5 (2020).
46 Ballard, Z. S. J., H.A., Goncharov, A.; Liang, J.; Nugroho, K.; Carlo, D.D.; Garner O.B.; Ozcan, A. Deep learning-enabled point-of-care sensing using multiplexed paper-based sensors. npj Digital Medicine 3, doi:https://doi.org/10.1038/s41746-020-0274-y (2020).
47 Choi, C. H., Zuckerman, J. E., Webster, P. & Davis, M. E. Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci U S A 108, 6656-6661, doi:10.1073/pnas.1103573108 (2011).
48 Tauriello, D. V. F. et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538-543, doi:10.1038/nature25492 (2018).
49 Chakladar, S. et al. A mechanism-based inactivator of glycoside hydrolases involving formation of a transient non-classical carbocation. Nat Commun 5, 5590, doi:10.1038/ncomms6590 (2014).